| 摘要 |
Provided is an anti-NRP1 antibody capable of inhibiting NRP1's interaction with vascular endothelial cell growth factor (VEGF) comprising a light chain variable domain comprising a specified sequence of CDRL1, CDRL2 and CDRL3. The antibody can be used to inhibit NRP1 mediated angiogenesis in various cancers. |
